Factor Therapeutics Ltd (FTT)

Snapshot

FTT's Principal Activity is the identification and diligence of potential new business opportunities for the Company.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Mr Stephen Kelly	Chief Financial Officer,Joint Company Secretary	Oct 2021
Dr David Lionel Brookes	Non-Executive Director,Non-Executive Chairman	Apr 2019	Dr David Lionel Brookes Non-Executive Director,Non-Executive Chairman Dr Brookes has experience in the health and biotechnology industries and is currently a Non-Executive director of Anatara Ltd (ASX:ANR) and TALi Digital Limited (ASX:TD1). He has previously been a director of several other ASX listed biotechnology companies, most recently as the Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc in June 2018. Until its acquisition in January 2021, Dr Brookes was Non-Executive Chairman of the Better Medical Group, and maintains roles as a clinician and a biotechnology industry consultant. He is Member of Risk Management Committee.
Mr John Michailidis	Non-Executive Director	Feb 2017	Mr John Michailidis Non-Executive Director Mr Michailidis is currently the Managing Director for TEVA Australia/NZ and brings over 30 years of commercial pharmaceutical experience to Factor, most recently as Managing Director for TEVA, Australia and New Zealand. His career has ranged from global franchise and regional executive leadership roles with F. Hoffman - La Roche (Roche) to CEO experience with growth-stage biopharmaceutical companies, such as AviPep and Orphan Australia (acquired by Sigma). He is Chair of Risk Management Committee.
Ms Melanie Farris	Non-Executive Director,Joint Company Secretary	Sep 2016	Ms Melanie Farris Non-Executive Director,Joint Company Secretary Ms Farris is an experienced governance and corporate operations professional and non-executive director with over 13 years' experience in listed life sciences companies, as well as experience in the planning, management and delivery of strategic corporate activities including IPO and M&A due diligence and integration. Ms Farris previously served as Non-Executive Director and Company Secretary for Invion Limited (ASX: IVX); and Chairperson of Synapse Australia Limited. She is currently Chief Governance and Risk Officer and Group Company Secretary for Telix Pharmaceuticals Limited (ASX:TLX).

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
27/09/21	Melanie Farris	Issued	204,525	$0.04	$8,181	Director remuneration
27/09/21	David Brookes	Issued	1,121,250	$0.04	$44,850	Director remuneration

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
John Michailidis	27/09/2021	0	862,143	100,000	N/A
Melanie Farris	27/09/2021	204,525	N/A	25,000	N/A
David Brookes	27/09/2021	0	1,280,000	500,000	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Calama Holdings Pty Ltd	40,000,000	3.84%
GP Securities Pty Ltd	28,607,989	2.74%
Citicorp Nominees Pty Limited	24,261,921	2.33%
Yelwac Pty Ltd	22,594,216	2.17%
Symington Pty Ltd	19,700,000	1.89%
HSBC Custody Nominees (Australia) Limited	16,314,861	1.56%
Mr Jules Christian Wilson	15,099,502	1.45%
Dr Alok Jhamb	15,000,000	1.44%
Mr Francis Xavier Parnis & Mrs Sally Jane Parnis	14,554,598	1.40%
Mr Michael Andrew Whiting & Mrs Tracey Anne Whiting	12,876,085	1.23%
Nurragi Investments Pty Ltd	12,850,000	1.23%
Mr Kevin John Day	12,500,000	1.20%
Mr Konstandinos Emmanouil	12,000,000	1.15%
Harold Cripps Holdings Pty Ltd	11,623,027	1.11%
Mr Anthony Bratton	10,986,115	1.05%
Jetosea Pty Ltd	10,000,000	0.96%
Aglub Investments Pty Ltd	9,945,731	0.95%
Ms Pharoth San & Mr Kaden San	9,500,000	0.91%
Gattenside Pty Ltd	9,033,037	0.87%
Queensland University Of Technology	8,087,010	0.78%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.003	30 June
2019	$0.004	28 June
2018	$0.047	29 June
2017	$0.062	28 June
2016	$0.034	28 June

FTT Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.